Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,938 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, Miyakawa J, Nakamura Y, Hoshina H, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Adachi Y, Sugimoto K, Sato K, Tabata M, Tanaka T, Nara K, Uemura Y, Kamei J, Akiyama Y, Sato Y, Yamada Y, Niimi A, Yamada D, Takada T, Takahashi S, Yamada Y, Miyazaki H, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: miyazaki h. Int J Urol. 2024 Nov 22. doi: 10.1111/iju.15640. Online ahead of print. Int J Urol. 2024. PMID: 39575880
ASO Visual Abstract: Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Hashimoto D, Satoi S, Yamaki S, Nakayama S, Shibata N, Matsumura K, Miyazaki H, Matsui Y, Tsybulskyi D, Sang NT, Ikeura T, Kanai M, Sekimoto M. Hashimoto D, et al. Among authors: miyazaki h. Ann Surg Oncol. 2024 Nov 14. doi: 10.1245/s10434-024-16502-3. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39542964 No abstract available.
Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Hashimoto D, Satoi S, Yamaki S, Nakayama S, Shibata N, Matsumura K, Miyazaki H, Matsui Y, Tsybulskyi D, Sang NT, Ikeura T, Kanai M, Sekimoto M. Hashimoto D, et al. Among authors: miyazaki h. Ann Surg Oncol. 2025 Jan;32(1):517-528. doi: 10.1245/s10434-024-16361-y. Epub 2024 Oct 21. Ann Surg Oncol. 2025. PMID: 39433718
1,938 results